GlassScriptPhysician profile
Russell Spadaro
NPI 1619948445
$2,698.98
in general payments reported to CMS, 2019-2025
20 companies · $316 in 2025
The $316 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $91.55 · 2021: $234 · 2022: $480 · 2023: $633 · 2024: $290 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $394.79 | 2019-2024 | Jornay Pm |
| Corium, LLC | $391.52 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $312.83 | 2019-2025 | Vaxneuvance, Enflonsia, Proquad |
| Tris Pharma INC | $231.77 | 2019-2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Regeneron Healthcare Solutions, INC. | $221.86 | 2024-2025 | Dupixent |
| Supernus Pharmaceuticals, INC. | $220.20 | 2021-2022 | |
| Dermira, INC. | $122.63 | 2019 | |
| Novo Nordisk INC | $116.99 | 2024 | Wegovy |
| Glaxosmithkline, LLC. | $109.72 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.11 | 2025 | |
| Neos Therapeutics, LP | $91.08 | 2019-2020 | |
| Celgene Corporation | $83.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.12 | 2020-2021 | |
| Shire North American Group INC | $55.92 | 2019 | |
| Adlon Therapeutics L.P. | $44.46 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $37.96 | 2023 | |
| Cranial Technologies, INC | $31.77 | 2019-2022 | |
| Phadia US INC. | $29.29 | 2021-2023 | Immunocap |
| Noven Therapeutics, LLC | $21.44 | 2023 | Xelstrym |
| Seqirus USA INC | $15.13 | 2023 | Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Spadaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.